Cargando…

Severe Systemic Rash in the Treatment of Hairy Cell Leukemia with Cladribine: Case Report and Literature Review

A 49-year-old male patient who had been diagnosed with variable hairy cell leukemia (HCL-V) was treated with interferon for half a year but exert no obvious effect. After two courses of chemotherapy with cladribine, he achieved remission, and splenomegaly significantly improved (the length in cranio...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Huijie, Shen, Yingying, Shen, Yiping, Wu, Dijiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682778/
https://www.ncbi.nlm.nih.gov/pubmed/33239902
http://dx.doi.org/10.2147/IJGM.S281476
_version_ 1783612745528115200
author Dong, Huijie
Shen, Yingying
Shen, Yiping
Wu, Dijiong
author_facet Dong, Huijie
Shen, Yingying
Shen, Yiping
Wu, Dijiong
author_sort Dong, Huijie
collection PubMed
description A 49-year-old male patient who had been diagnosed with variable hairy cell leukemia (HCL-V) was treated with interferon for half a year but exert no obvious effect. After two courses of chemotherapy with cladribine, he achieved remission, and splenomegaly significantly improved (the length in craniocaudal dimension decreased from 15.8cm to 11.8cm). Four years later, the patient got disease relapse and was recommended for another cycle of cladribine (6mg for 7 days). On the last day of cladribine, the patient developed fever with needle-like red rashes on the face, limbs, and trunk. At the very beginning, the rash was lighter in color, sparsely distributed, and without obvious itching. Three days later, the rash gradually darkened, expanded and merged, with itching. With the application of high dose gamma globulin and corticosteroids (prednisolone combined with dexamethasone), the rash finally faded, and the patient was discharged. Rash caused by cladribine is not uncommon, such serious and widespread drug-induced rash is rare, and there are few reports. This article reviewed relevant studies and treatments.
format Online
Article
Text
id pubmed-7682778
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-76827782020-11-24 Severe Systemic Rash in the Treatment of Hairy Cell Leukemia with Cladribine: Case Report and Literature Review Dong, Huijie Shen, Yingying Shen, Yiping Wu, Dijiong Int J Gen Med Case Report A 49-year-old male patient who had been diagnosed with variable hairy cell leukemia (HCL-V) was treated with interferon for half a year but exert no obvious effect. After two courses of chemotherapy with cladribine, he achieved remission, and splenomegaly significantly improved (the length in craniocaudal dimension decreased from 15.8cm to 11.8cm). Four years later, the patient got disease relapse and was recommended for another cycle of cladribine (6mg for 7 days). On the last day of cladribine, the patient developed fever with needle-like red rashes on the face, limbs, and trunk. At the very beginning, the rash was lighter in color, sparsely distributed, and without obvious itching. Three days later, the rash gradually darkened, expanded and merged, with itching. With the application of high dose gamma globulin and corticosteroids (prednisolone combined with dexamethasone), the rash finally faded, and the patient was discharged. Rash caused by cladribine is not uncommon, such serious and widespread drug-induced rash is rare, and there are few reports. This article reviewed relevant studies and treatments. Dove 2020-11-19 /pmc/articles/PMC7682778/ /pubmed/33239902 http://dx.doi.org/10.2147/IJGM.S281476 Text en © 2020 Dong et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Dong, Huijie
Shen, Yingying
Shen, Yiping
Wu, Dijiong
Severe Systemic Rash in the Treatment of Hairy Cell Leukemia with Cladribine: Case Report and Literature Review
title Severe Systemic Rash in the Treatment of Hairy Cell Leukemia with Cladribine: Case Report and Literature Review
title_full Severe Systemic Rash in the Treatment of Hairy Cell Leukemia with Cladribine: Case Report and Literature Review
title_fullStr Severe Systemic Rash in the Treatment of Hairy Cell Leukemia with Cladribine: Case Report and Literature Review
title_full_unstemmed Severe Systemic Rash in the Treatment of Hairy Cell Leukemia with Cladribine: Case Report and Literature Review
title_short Severe Systemic Rash in the Treatment of Hairy Cell Leukemia with Cladribine: Case Report and Literature Review
title_sort severe systemic rash in the treatment of hairy cell leukemia with cladribine: case report and literature review
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682778/
https://www.ncbi.nlm.nih.gov/pubmed/33239902
http://dx.doi.org/10.2147/IJGM.S281476
work_keys_str_mv AT donghuijie severesystemicrashinthetreatmentofhairycellleukemiawithcladribinecasereportandliteraturereview
AT shenyingying severesystemicrashinthetreatmentofhairycellleukemiawithcladribinecasereportandliteraturereview
AT shenyiping severesystemicrashinthetreatmentofhairycellleukemiawithcladribinecasereportandliteraturereview
AT wudijiong severesystemicrashinthetreatmentofhairycellleukemiawithcladribinecasereportandliteraturereview